The Leukemia & Lymphoma Society (LLS) ran the Screen to Lead Program (SLP) in FY13, FY14, and FY17. This grant awards qualified academic laboratories for support of drug discovery specifically directed towards medicinal chemistry and/or drug target screening in hematological malignancies. LLS recognizes a significant need for investigators to receive resources for high-throughput screening and/or optimization of small molecules into drug-like compounds. These grants were peer reviewed by a special committee and were awarded for two years. Should the LLS reopen this program, an announcement will be posted on this page. Questions about the program can be directed to James.Kasper@lls.org.
The Screen to Lead Program will be open for new applications starting in May.
|Call for Proposals||May 2018|
|Full Application Deadline||July 31, 2018|
|Scientific Peer Review Committee||October 2018|
|Notification of Awards||February 2019|
|Contract and Lay Abstracts Due||June 3, 2019|
|Anticipated Funding Start Date||July 1, 2019|